Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.80)
# 3,811
Out of 4,876 analysts
47
Total ratings
25.71%
Success rate
-16.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $6.18 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $48.03 | - | 2 | Jun 10, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $21.32 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $5.59 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $3.30 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $8.81 | +47.67% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $2.70 | - | 2 | Mar 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $46.70 | - | 4 | Feb 19, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $70.81 | - | 6 | Jan 10, 2025 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $33.65 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.92 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $96 | $29.83 | +221.82% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $32.02 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $126.92 | +130.07% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $443.40 | -16.55% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.12 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.34 | - | 1 | May 30, 2017 |
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $6.18
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $48.03
Upside: -
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $21.32
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.59
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.30
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $8.81
Upside: +47.67%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.70
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $46.70
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $70.81
Upside: -
Agios Pharmaceuticals
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $33.65
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.92
Upside: -
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $29.83
Upside: +221.82%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.02
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $126.92
Upside: +130.07%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $443.40
Upside: -16.55%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.12
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.34
Upside: -